Dyne Therapeutics (NASDAQ:DYN) Stock Rating Lowered by JPMorgan Chase & Co.

Dyne Therapeutics (NASDAQ:DYN) was downgraded by stock analysts at JPMorgan Chase & Co. from an “overweight” rating to a “neutral” rating in a research note issued on Thursday, MarketBeat.com reports. They presently have a $35.00 price target on the stock, down from their previous price target of $43.00. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 13.90% from the stock’s current price.

A number of other analysts have also recently issued reports on the stock. Morgan Stanley lifted their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the company an “overweight” rating in a research note on Wednesday, August 14th. Oppenheimer reiterated an “outperform” rating and issued a $55.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. HC Wainwright restated a “buy” rating and set a $55.00 target price on shares of Dyne Therapeutics in a report on Wednesday, September 4th. Guggenheim upped their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. Finally, Stifel Nicolaus raised their price objective on Dyne Therapeutics from $41.00 to $66.00 and gave the company a “buy” rating in a research note on Friday, August 16th. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Dyne Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $50.60.

Dyne Therapeutics Trading Down 1.2 %

NASDAQ DYN opened at $30.73 on Thursday. The company has a market capitalization of $2.69 billion, a PE ratio of -7.74 and a beta of 1.05. Dyne Therapeutics has a 1-year low of $6.40 and a 1-year high of $47.45. The firm’s fifty day simple moving average is $36.34 and its 200-day simple moving average is $34.66.

Dyne Therapeutics (NASDAQ:DYN) last posted its quarterly earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. As a group, analysts predict that Dyne Therapeutics will post -2.96 EPS for the current year.

Insider Activity

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the sale, the director now directly owns 234,127 shares of the company’s stock, valued at $8,533,929.15. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, SVP Richard William Scalzo sold 1,390 shares of the business’s stock in a transaction that occurred on Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total transaction of $48,024.50. Following the sale, the senior vice president now directly owns 98,568 shares in the company, valued at approximately $3,405,524.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Dirk Kersten sold 79,411 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the completion of the transaction, the director now directly owns 234,127 shares of the company’s stock, valued at approximately $8,533,929.15. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 158,975 shares of company stock valued at $5,693,789. 20.77% of the stock is owned by company insiders.

Institutional Investors Weigh In On Dyne Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. boosted its holdings in Dyne Therapeutics by 67.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,310 shares of the company’s stock valued at $694,000 after purchasing an additional 7,812 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Dyne Therapeutics by 24.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,631 shares of the company’s stock worth $123,000 after buying an additional 709 shares during the period. Values First Advisors Inc. acquired a new stake in Dyne Therapeutics in the 3rd quarter valued at $62,000. Creative Planning grew its position in Dyne Therapeutics by 41.5% in the third quarter. Creative Planning now owns 10,605 shares of the company’s stock valued at $381,000 after acquiring an additional 3,111 shares during the period. Finally, Handelsbanken Fonder AB raised its stake in Dyne Therapeutics by 21.4% during the third quarter. Handelsbanken Fonder AB now owns 19,300 shares of the company’s stock worth $693,000 after acquiring an additional 3,400 shares in the last quarter. Institutional investors own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.